Fundraising FoxCour Pharma
5 known investors
Find your way into Cour Pharma
Sign up to see every warm intro you have to Cour Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cour Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.
Investors · 5
Alpha Wave Global✓ confirmed by Cour PharmaMiami
How we know: the company's own site · Alpha Wave Global's portfolio page · Not right? Tell us
Lumira Ventures✓ confirmed by Cour PharmaToronto · $1M – $10M
How we know: Lumira Ventures's portfolio page · the company's own site · Not right? Tell us
Related companies · 3
Collegium PharmaceuticalCollegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Cour Pharma.
Frequently asked questions
- What does Cour Pharma do?
- COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.
- Who are Cour Pharma's investors?
- Cour Pharma's investors include Alpha Wave Global, Lumira Ventures, Roche Venture Fund, Angelini Ventures, JDRF T1D Fund.